Filtered By:
Condition: Atrial Fibrillation
Countries: Denmark Health

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 102 results found since Jan 2013.

Different Risk Profiles of European Patients Using Direct Oral Anticoagulants or Vitamin K Antagonists: a Rapid Review
AbstractPurpose of ReviewWe investigated the risk profiles of patients using direct oral anticoagulants (DOAC) or vitamin K antagonists (VKA) in European cohort studies to estimate the importance of potential (measured or unmeasured) confounding factors in analyses comparing these drugs. We searched MEDLINE and EMBASE (2008 –2018) for relevant studies and extracted information on age, sex, comorbidity, Charlson comorbidity index, HAS-BLED score (assessing risk of bleeding) and CHA2DS2-VASc score (assessing risk of stroke).Recent FindingsOverall, 66 studies with 2,808,757 patients were included. Most patients were from Fr...
Source: Current Epidemiology Reports - November 14, 2020 Category: Epidemiology Source Type: research

Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation.
CONCLUSION: In patients with AF, DM increases the risk of ischemic stroke, regardless of treatment. PMID: 33130017 [PubMed - as supplied by publisher]
Source: Vascular Pharmacology - October 28, 2020 Category: Drugs & Pharmacology Authors: Jensen T, Olesen KKW, Caterina, Würtz M, Kristensen SD, Maeng M Tags: Vascul Pharmacol Source Type: research

Long ‐term risk of heart failure and mortality following mitral valve surgery in patients with and without right ventricular pacemaker
ConclusionsPostoperative implantation of a permanent RV pacemaker does not alter the long ‐term risks of HF and mortality following mitral valve surgery.
Source: Journal of Cardiac Surgery - September 27, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Charlotte Andersson, Morten Schou, Gunnar H. Gislason, Lars K øber, Christian Torp‐Pedersen, Kevin M. Monahan Tags: ORIGINAL ARTICLE Source Type: research

Thromboembolic events related to atrial fibrillation during the COVID-19 epidemic in Denmark
The COVID-19 epidemic has threatened to overwhelm the health-care systems of European countries resulting in government decisions of extensive societal lockdowns. There have been considerable concerns regarding the collateral effects of the COVID-19 epidemic overshadowing the care of patients with other medical conditions including cardiovascular diseases. Of interest, decreases in the registered incidences of atrial fibrillation (AF) and ischemic stroke have been reported [1,2]. AF is a common reason for physician contact and AF patients are often recommended treatment with oral anticoagulants to mitigate the associated r...
Source: Thrombosis Research - July 29, 2020 Category: Hematology Authors: Peter Vibe Rasmussen, Paul Blanche, Jarl Emanuel Strange, Jawad Haider Butt, Frederik Dalgaard, Kristian Kragholm, Matthew Phelps, Gunnar Gislason, Morten Lock Hansen Tags: Letter to the Editors-in-Chief Source Type: research

Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation
AbstractUsing nationwide Danish registries, we conducted a population-based case-crossover study evaluating the association between switching from a vitamin K antagonist (VKA) to a direct oral anticoagulant (DOAC), and vice versa, and 30-day risks of bleeding and arterial thromboembolism in patients with atrial fibrillation (AF). The case-crossover population was identified among oral anticoagulant users during 2011 –2018 (n = 123,217) as patients with AF with 1) a case-defining outcome and 2) an anticoagulant switch during the 180 days preceding the outcome. Odds ratios were estimated using conditional logistic regres...
Source: American Journal of Epidemiology - July 8, 2020 Category: Epidemiology Source Type: research

Using the Case-crossover Design to Assess Short-term Risks of Bleeding and Arterial Thromboembolism Following Switching Between Oral Anticoagulants in a Population-based Cohort of Atrial Fibrillation Patients.
Abstract Using nationwide Danish registries, we conducted a population-based case-crossover study evaluating the association between switching from a vitamin K antagonist (VKA) to a direct oral anticoagulant (DOAC), and vice-versa, and 30-day risks of bleeding and arterial thromboembolism in atrial fibrillation (AF) patients. The case-crossover population was identified among oral anticoagulant users during 2011-2018 (n = 123,217), as AF patients with (a) a case-defining outcome and (b) an anticoagulant switch during the 180 days preceding the outcome. Odds Ratios were estimated using conditional logistic regres...
Source: Am J Epidemiol - July 7, 2020 Category: Epidemiology Authors: Hellfritzsch M, Wang SV, Grove EL, Gagne JJ, Hallas J, Pottegård A Tags: Am J Epidemiol Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Depression and Uptake of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation: A Danish Nationwide Cohort Study
Conclusions: Comorbid depression was associated with a significantly lower OAT uptake in patients with AF, which questions whether depressed patients receive sufficient support to manage this consequential cardiac condition. However, a substantial increase in the overall OAT uptake and a decrease of the depression-associated deficit in OAT were seen over the period during which OAT was developed through the introduction of new oral anticoagulation therapy.
Source: Medical Care - February 13, 2020 Category: Health Management Tags: Original Articles Source Type: research

A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial
Publication date: Available online 7 November 2019Source: The Lancet NeurologyAuthor(s): Michael Ahmadi, Inga Laumeier, Thomas Ihl, Maureen Steinicke, Caroline Ferse, Matthias Endres, Armin Grau, Sidsel Hastrup, Holger Poppert, Frederick Palm, Martin Schoene, Christian L Seifert, Farid I Kandil, Joachim E Weber, Paul von Weitzel-Mudersbach, Martin L J Wimmer, Ale Algra, Pierre Amarenco, Jacoba P Greving, Otto BusseSummaryBackgroundPatients with recent stroke or transient ischaemic attack are at high risk for a further vascular event, possibly leading to permanent disability or death. Although evidence-based treatments for ...
Source: The Lancet Neurology - November 8, 2019 Category: Neurology Source Type: research

Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation
Conclusions: Research on the long-term comparative effectiveness, safety, and effects on quality of life between rivaroxaban and other novel oral anticoagulants is urgently needed.
Source: American Journal of Therapeutics - November 1, 2019 Category: Drugs & Pharmacology Tags: Review Source Type: research

Early and late risk of ischemic stroke after TAVR as compared to a nationwide background population
In conclusion, TAVR was associated with an increased risk of ischemic CVE in the early phase, but not in the late phase, as compared to their matched con trols—OAC therapy reduced this early risk of ischemic CVE by half.
Source: Clinical Research in Cardiology - October 29, 2019 Category: Cardiology Source Type: research

Usefulness of CHA2DS2-VASc Score to Predict Stroke Risk Independent of Atrial
We examined whether a CHA2DS2-VASc score predicts stroke risk among individuals without hospital-diagnosed AF and quantified the magnitude of the association in comparison to AF patients. We used data from population-based medical registries (1995 –2005) covering all Danish hospitals to identify patients diagnosed with AF (n=122,980). We matched ≤5 non-AF individuals (n=612,723) to each AF patient on the individual risk factors included in the CHA2DS2-VASc score.
Source: The American Journal of Cardiology - July 14, 2019 Category: Cardiology Authors: Anne Gulbech Ording, Erzs ébet Horváth-Puhó, Paolo Prandoni, Michelle Zippora Leisner, Dóra Körmendiné Farkas, Flemming Hald Steffensen, Morten Olsen, Henrik Toft Sørensen, Morten Schmidt Source Type: research

Usefulness of CHA2DS2-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation
We examined whether a CHA2DS2-VASc score predicts stroke risk among individuals without hospital-diagnosed AF and quantified the magnitude of the association in comparison to AF patients. We used data from population-based medical registries (1995 to 2005) covering all Danish hospitals to identify patients diagnosed with AF (n  = 122,980). We matched ≤5 non-AF individuals (n = 612,723) to each AF patient on the individual risk factors included in the CHA2DS2-VASc score.
Source: The American Journal of Cardiology - July 14, 2019 Category: Cardiology Authors: Anne Gulbech Ording, Erzs ébet Horváth-Puhó, Paolo Prandoni, Michelle Zippora Leisner, Dóra Körmendiné Farkas, Flemming Hald Steffensen, Morten Olsen, Henrik Toft Sørensen, Morten Schmidt Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk.
CONCLUSION: Risk of cardiovascular disease was found increased in untreated hyperthyroid patients, and duration of decreased TSH associated with increasing risk of cardiovascular outcomes in both treated and untreated hyperthyroid individuals. This suggests that increased cardiovascular risk is not only driven by lack of treatment but also by insufficient therapy. Our results support timely treatment and careful monitoring of hyperthyroid patients in order to reduce cardiovascular risk. PMID: 30648498 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - January 18, 2019 Category: Endocrinology Tags: Thyroid Source Type: research